EUVIMEDEUVIMED entdecken
Crossref

Upregulation of PLOD2 as a Potential Biomarker Associated with Poor Prognosis and Immune Infiltration in Glioma

Frontiers in Medical Science Research · 2026 · 8 (2)

DOI: 10.25236/fmsr.2026.080205 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Medical Science Research, 2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 (PLOD2), a key enzyme in collagen cross-linking, is overexpressed in various solid tumors and plays an important role in tumor invasion and metastasis. However, the potential prognostic significance of PLOD2 in glioma remains unclear. Here, we analyzed PLOD2 expression across multiple cancer types using the GEPIA2, TIMER2.0, and UALCAN databases, and confirmed that PLOD2 expression was significantly elevated in glioma tissues compared to corresponding normal tissues. Furthermore, high PLOD2 expression was associated with poor prognosis in glioma patients. Additionally, we utilized the Chinese Glioma Genome Atlas (CGGA) to investigate the association between PLOD2 and the clinicopathological and molecular characteristics of glioma patients. Our findings revealed that PLOD2 expression was positively correlated with tumor malignancy (e.g., higher WHO grade). Further analysis of the biological role of PLOD2 in glioma indicated its involvement in multiple biological processes implicated in glioma development, including immune responses, inflammatory responses, and the regulation of defense responses within the immune system. Immune infiltration analysis using the CIBERSORT database uncovered correlations between high PLOD2 expression and the infiltration of various immune cell types, as well as immune checkpoints, in glioma. In summary, this study reveals that PLOD2 is a key molecule in the malignant progression of glioma, serving not only as a potential diagnostic biomarker for GBM but also as a promising novel therapeutic target for improving glioma treatment.

Zitieren

APA

(2026). Upregulation of PLOD2 as a Potential Biomarker Associated with Poor Prognosis and Immune Infiltration in Glioma. Frontiers in Medical Science Research, 8(2). https://doi.org/10.25236/fmsr.2026.080205

Vancouver

Upregulation of PLOD2 as a Potential Biomarker Associated with Poor Prognosis and Immune Infiltration in Glioma. Frontiers in Medical Science Research. 2026;8(2). doi:10.25236/fmsr.2026.080205

BibTeX
@article{euvimed2026,
  title = {Upregulation of PLOD2 as a Potential Biomarker Associated with Poor Prognosis and Immune Infiltration in Glioma},
  journal = {Frontiers in Medical Science Research},
  year = {2026},
  volume = {8},
  number = {2},
  doi = {10.25236/fmsr.2026.080205}
}
Kostenlos starten →